Current location:business >>
WHO endorses China's Sinopharm COVID
business85People have gathered around
IntroductionWorkers prepare to unload the COVID-19 vaccines from China at the Baghdad International Airport in B ...
Workers prepare to unload the COVID-19 vaccines from China at the Baghdad International Airport in Baghdad, Iraq, April 11, 2021. [Photo/Xinhua]
The World Health Organization (WHO) validated on Friday the COVID-19 vaccine developed by China's Sinopharm for emergency use, a move set to boost global vaccine rollout, particularly in the developing world.
"This afternoon, the WHO gave emergency use listing to Sinopharm Beijing's COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality," said WHO Director General Dr. Tedros Adhanom Ghebreyesus at a press briefing.
"This expands the list of vaccines that COVAX can buy and gives countries confidence to expedite their own regulatory approval, and to import and administer a vaccine," he said.
COVAX is a global coalition that works to ensure fair and equitable access to COVID-19 vaccines around the world.
In addition to the Sinopharm's BBIBP-CorV vaccine, the WHO had previously listed the COVID-19 vaccine developed by Pfizer/BioNTech, two versions of the AstraZeneca/Oxford vaccine, the Janssen vaccine and the Moderna vaccine for emergency use.
In an official press release, WHO Assistant Director General for Access to Health Products Dr. Mariangela Simao said that the addition of the Sinopharm vaccine has "the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk."
First COVID-19 jab with vial monitor
The jab produced by the Beijing Bio-Institute of Biological Products Co. Ltd., a subsidiary of the China National Biotec Group, is an inactivated vaccine with easy storage requirements, which makes it highly suitable for use in low-resource settings.
It is also the first vaccine that will carry a vial monitor, a small sticker on the vials that changes color if the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
According to the WHO's Strategic Advisory Group of Experts on Immunization (SAGE), the Sinopharm vaccine is recommended for use in adults 18 years and older in a two-dose schedule with a spacing of three to four weeks.
Though few adults over 60 years were enrolled in clinical trials and efficacy could not be estimated in this age group, the WHO is not recommending an upper age limit for the Sinopharm vaccine, because reviewed data have suggested that the vaccine is likely to have a protective effect in older persons, according to the WHO press release.
"There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations," said the WHO press release, which recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring.
Assessment by SAGE has shown that the Sinopharm vaccine had been authorized by 45 countries or jurisdictions for use in adults 18 years or older, where more than 65 million doses had been administered through emergency use programs. No safety concerns have been identified from pre-clinical or repro/tox (reproductive toxicity) studies, while most adverse events were mild to moderate, such as injection pain, headache and fatigue.
Global public good
As of Wednesday, more than 1.1 billion COVID-19 vaccine doses had been administered globally, but over 80 percent of those had been administered in high and upper-middle income countries, while just 0.3 percent in low-income countries, according to Tedros.
With the WHO's validation for emergency use, the Sinopharm vaccine, as the first COVID-19 vaccine developed by a non-western country, is expected to accelerate vaccine rollout in many low and middle-income countries through purchase and delivery by the WHO-led COVAX initiative.
According to Yu Qingming, chairman of the Sinopharm Group, this year's output of the Sinopharm vaccine is targeted at more than one billion doses, and is expected to reach three billion doses in the future.
China has decided to provide ten million COVID-19 vaccine doses to the COVAX initiative to meet the urgent needs of developing countries, a concrete step to deliver on the promise to make vaccines a global public good.
This is also an important achievement in the field of epidemic prevention and control. China was the first to have put the pandemic under control, and successfully developed one of the earliest vaccines in the world.
Adhering to the concept of a community with a shared future for health, China has so far provided vaccine assistance selflessly to more than 80 countries and three international organizations, exported vaccines to more than 40 countries, and collaborated with over ten countries in vaccine research and development (R&D) and production.
The validation of the Chinese vaccine, which is the result of high technology content and high R&D investment, has also strengthened the international recognition of the "Made in China" and "R&D in China labels."
Tags:
Reprint:Friends are welcome to share on the Internet, but please indicate the source of the article when reprinting it.“Global Gaze news portal”。http://nicaragua.lochsaege.com/article-24b099901.html
Related articles
Hall of Fame outfielder Ken Griffey Jr. to lead Indianapolis 500 field in Corvette pace car
businessINDIANAPOLIS (AP) — Hall of Fame outfielder Ken Griffey Jr. will drive the pace car for the 108th ru ...
【business】
Read moreBack to countryside, new trend amid China's rural revitalization drive
business(Xinhua) 09:52, February 24, 2024* Throughout the history of human development, rural decline in the ...
【business】
Read moreChina to build pilot zones for special needs education reform
business(Xinhua) 10:07, April 10, 2024BEIJING, April 9 (Xinhua) -- China will build a batch of pilot zones a ...
【business】
Read more
Popular articles
- Biden says Brown v. Board of Education ruling was about more than education
- Taiwan students can apply for mainland universities from March 1
- 2024 Int'l Tourism Fair held in Madrid, Spain
- Rashee Rice 'was driving his Lamborghini at 119mph' in the seconds before causing a multi
- Kristin Cavallari, 37, ignores critics of her age
- Chinese new energy vehicle sector speeds up expansion overseas
Latest articles
Young Boys seals 6th Swiss soccer league title in 7 years after rallying from firing coach Wicky
How China's rest stations for outdoor workers create prospects for new employment forms
China's road logistics price index dips
China to build an investors
Tom Brady and Jay
Pilot carbon sink trading yields profit, eco benefits in rural China
LINKS
- Tardy claims maiden LPGA title at Blue Bay in China
- Liaoning withstand Shanxi rally to win in OT
- Qingdao top Ningbo, Sichuan losing skid reaches 18
- Eberl ringing alarm bells for Bayern ahead of Arsenal duel
- Armenia insists top UN court has jurisdiction to hear case accusing Azerbaijan of racial hatred
- Singapore's outgoing prime minister will stay on as senior minister, his successor says
- 'Village Super League' draws global football enthusiasts
- Armenia insists top UN court has jurisdiction to hear case accusing Azerbaijan of racial hatred
- Israel must stop settler attacks on Palestinians, UN office says
- 2nd Hong Kong pop culture festival to open on April 6